Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no clinical studies on the reduction of viral load in patients with COVID-19. This study investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimen in patients with mild COVID-19.

This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of lopinavir/ritonavir, hydroxychloroquine, or control arm.

Inclusion Criteria:

• confirmed mild COVID-19 (NEWS scoring system 0-4)

Exclusion Criteria:

• unable to take oral medication
• pregnancy or breast feeding
• immunocompromised patients
• creatinine clearance (CCL) < 30 mL/min
• aspartate transaminase (AST) or alanine transaminase (ALT) > 5 times Upper limit of normal (ULN)